Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Multiple Myeloma Lytic Lesions- Chemo/Radiation Weakens Bones-
Multiple Myeloma Lytic Lesions- Chemo/Radiation Weakens Bones-
Bone loss that can lead to osteoporosis and fractures is a major problem for (multiple myeloma) patients who receive chemotherapy and radiation.
You’ve been diagnosed with a blood cancer that is incurable and eats your bones causing lytic lesions. The study linked below explains how chemotherapy and radiation, the therapies that conventional oncology considers “potentially curative” to also cause your bones to weaken. In effect, both multiple myeloma and chemotherapy can cause lytic lesions.
To make matters worse for multiple myeloma patients and survivors, as the second study linked below explains, dexamethasone (dex) suppresses bone formation.
Finally, studies confirm that chemotherapy regimens such as Velcade cause multiple myeloma to become more aggressive. Conventional chemotherapy then causes your MM to relapse and causes your lytic lesion to worsen.
The point I’m trying to make here is that conventional FDA approved chemotherapy, both Velcade and Dexamethasone specifically, cause as many problems as they solve. Yes, I agree that multiple myeloma patients need chemo. But not at the doses called for in standard-of-care protocols.
Consider evidence-based integrative therapies shown to enhance the efficacy of chemotherapy.
For example
are both documented as enhancing Velcade, the chemo shown to cause lytic lesions and to cause MM to relapse. While we’re talking about curcumin and C-B-D oil, both are bone strengthening therapies and both are cytotoxic to MM by themselves.
If, as the third study linked below discusses, Velcade causes inflammation, could MM patients take anti-inflammatory supplements to, in effect, put out this inflammatory fire caused by chemo? The two answers I can offer are
- I’ve never read a study about this either way, pro or con and
- I take anti-inflammatory supplements daily and I’ve been in complete remission since 1999. So this might be an idea whose time has arrived.
I draw on my own MM experience to say that MM patients and survivors should employ as little conventional, toxic chemotherapy as possible in order to manage your multiple myeloma.
At the same time, I encourage multiple myeloma patients and survivors to employ evidence-based but non-toxic, non-conventional MM therapies such as curcumin, resveratrol, EGCG, Omega-3 fatty acids, frequent, moderate exercise, whole-body hyperthermia and others.
To learn more about these evidence-based but non-toxic MM therapies, scroll down the page, post a question or comment and I will reply to you ASAP.
Hang in there,
David Emerson
- MM Survivor
- MM Coach
- Director PeopleBeatingCancer
Recommended Reading:
- Multiple Myeloma Chemotherapy = Accelerated Aging
- Cancer Prehabilitation-
- Multiple Myeloma Patients-Add Organic Protein to Daily Diet
lytic lesion
(LIH-tik LEE-zhun) Destruction of an area of bone due to a disease process, such as cancer.
Investigational drugs block bone loss in mice receiving chemotherapy
“Studying mice, researchers have found a driver of bone loss related to cancer treatment. Radiation and chemotherapy can halt cell division in bone, which results in a stress response called senescence. This process is independent of hormones that affect bone health, such as estrogen…
Bone loss that can lead to osteoporosis and fractures is a major problem for cancer patients who receive chemotherapy and radiation…
Studying mice, researchers from Washington University School of Medicine in St. Louis have found a driver of bone loss related to cancer treatment. They have shown that radiation and chemotherapy can halt cell division in bone, which results in a stress response referred to as senescence. According to the new study, cell senescence drives bone loss in female mice beyond that seen from the absence of estrogen alone. The researchers further found that this process occurs in males and females and is independent of cancer type…
[Effects of different doses of dexamethasone on bone qualities in rats].
” Bone Mineral Density in Dex-L and the content of hydroxyproline in Dex-M reduced notably. Biomechanical property of Dex groups decreased significantly. Dex suppressed bone formation and reduced bone turnover significantly.
As the increase doses of Dex, %Tb. Ar increased, and, on the contrary, BMD and biomechanical property decreased with the reduced matrix in bone at the same time...”
Cancer treatment as a double-edged sword
“The researchers found that treatment with Velcade led to a physiological reaction that actually reinforced the intensity of the myeloma in the mice. According to Prof. Shaked, the drug caused inflammatory cells (macrophages) in the bone marrow to enhance the aggressiveness of the disease and provide the cancer cells with resistance to treatment.
“It is important to clarify that treatment with Velcade is essential and necessary,” says Prof. Shaked, “but its disadvantage is that along with the benefit there is damage.”